Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

16.81
Delayed Data
As of Sep 23
 +0.19 / +1.14%
Today’s Change
6.91
Today|||52-Week Range
18.00
+80.56%
Year-to-Date
Forget Novavax, Buy These 4 Biotech Stocks Instead
Sep 16 / Zacks.com - Paid Partner Content
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Sep 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close16.62
Today’s open16.89
Day’s range16.20 - 17.23
Volume2,476,041
Average volume (3 months)740,254
Market cap$727.6M
Dividend yield--
Data as of 09/23/2016

Growth & Valuation

Earnings growth (last year)-270.91%
Earnings growth (this year)+98.89%
Earnings growth (next 5 years)+19.10%
Revenue growth (last year)+119.16%
P/E ratioNM
Price/Sales3.58
Price/Book5.41

Competitors

 Today’s
change
Today’s
% change
TBRATobira Therapeutics ...-0.39-0.99%
CORTCorcept Therapeutics...0.000.00%
HRTXHeron Therapeutics I...-0.22-1.20%
AIMTAimmune Therapeutics...-0.39-2.30%
Data as of 09/23/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$109.9M
Annual profit (last year)-$39.9M
Net profit margin-36.27%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mihael Hristos Polymeropoulos
Chief Financial Officer, Treasurer &
Senior VP
James Patrick Kelly
Corporate headquarters
Washington, District Of Columbia

Forecasts

Search for Jobs